DIAGNOSIS OF UTERINE MYOMA BY USING BIOLOGICAL MARKERS

Abstract

Uterine myoma and the complications it causes in women remain not fully studied and are increasing, despite the advances in modern medicine. It is emphasized that uterine myoma is the most common gynecological disease over the past 5 years, and in women of reproductive age, this disease can also lead to infertility. In premenopausal women, uterine myoma can lead to heavy or prolonged menstrual bleeding, severe pelvic pain, and in severe cases, urinary incontinence. Our research aims to highlight the role of biological markers, such as CA-125, glycodelin, and vascular endothelial factor, in the early diagnosis of uterine myoma in women of any age. Early diagnosis and identification of these markers can help prevent the development of complications associated with uterine myoma.The study focuses on exploring the potential of these biological markers as tools for early detection and monitoring of uterine myoma. By understanding the relationship between the levels of these markers and the presence, severity, and progression of uterine myoma, healthcare providers can optimize diagnostic and treatment strategies, leading to improved patient outcomes. The findings of this research are expected to contribute to the advancement of knowledge in the field of gynecology, particularly in the area of uterine myoma management. The early identification of uterine myoma using reliable biomarkers can facilitate timely intervention, reduce the burden of complications, and enhance the overall quality of life for affected women.